Connect
← Return to Calcium and Vitamin D for bone density
Discussion
Calcium and Vitamin D for bone density
Osteoporosis & Bone Health | Last Active: Jan 29 8:02am | Replies (340)Comment receiving replies
Hi Theresa,
Vit D @ 30, take calcium 1200 daily. Osteoporosis due to 6 years on anastrazole for breast cancer. Prolia added 2 yrs. ago. Now intermittent severe pain in arms, wrists, hands. thigh and hip pain. Continuing calcium 1200 mg daily and Vit. D. Added glucosamine chondroitin and have had some relief. Also taking a break from anastrazole which is now recommended to take for 7-10 years. Do you have any info on organic calcium and Vit K2 for getting calcium into your bones?
Replies to "Hi Theresa, Vit D @ 30, take calcium 1200 daily. Osteoporosis due to 6 years on..."
@kahli One thing you may want to look at is Hydrolized Collagen our bones and organs need collagen I take bone meal powder 1 rounded teaspoon a day in smoothie or add to cereal. It is naturel but you will have to add a Vitamin D 3 I take 5000 units as my D was low on lab results. I get this from Amazon it is the Kal brand
Connect
Hello @kahli and @contentandwell,
I don't know much about organic calcium. I also have experienced a lot of bone pain from osteopenia.
Here is a link to an article from the National Institute of Health about Vit K2 helping to prevent fractures,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042573/
Here is the first paragraph of the article,
"Vitamin K may play an important role in the prevention of fractures in postmenopausal women with osteoporosis. Menatetrenone is the brand name of a synthetic vitamin K2 that is chemically identical to menaquinone-4. The present review study aimed to clarify the effect of menatetrenone on the skeleton in postmenopausal women with osteoporosis, by reviewing the results of randomized controlled trials (RCTs) in the literature. RCTs that investigated the effect of menatetrenone on bone mineral density (BMD), measured by dual-energy X-ray absorptiometry and fracture incidence in postmenopausal women with osteoporosis, were identified by a PubMed search for literature published in English. Eight studies met the criteria for RCTs. Small RCTs showed that menatetrenone monotherapy decreased serum undercarboxylated osteocalcin (ucOC) concentrations, modestly increased lumbar spine BMD, and reduced the incidence of fractures (mainly vertebral fracture), and that combined alendronate and menatetrenone therapy enhanced the decrease in serum ucOC concentrations and further increased femoral neck BMD. This review of the literature revealed positive evidence for the effects of menatetrenone monotherapy on fracture incidence in postmenopausal women with osteoporosis. Further studies are required to clarify the efficacy of menatetrenone in combination with bisphosphonates against fractures in postmenopausal women with osteoporosis."